Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Phenoxymethylpenicillin

Classification: B

Drug products: Avopenin, Fenoximetylpenicillin EQL Pharma, Fenoximetylpenicillin Orifarm, Kåvepenin®, Kåvepenin® Frukt, Peceve®, Phenoxymethylpenicillin EQL, Primve, Tikacillin

ATC code: J01CE02

Substances: phenoxymethylpenicillin

Summary

Controlled studies on differences between men and women regarding the effect, safety and pharmacokinetics of phenoxymethylpenicillin are lacking. A smaller study indicates that exposure of phenoxymethylpenicillin during pregnancy can be lower than in non-pregnant women, and dose adjustment thus can be needed.

Additional information

Pharmacokinetics and dosing

A pharmacokinetic study described changes in phenoxymethylpenicillin pharmacokinetics during pregnancy (12 pregnant women, 6 non-pregnant controls), in comparison to non-pregnancy. Following a single dose, half-life was shorter during the third trimester compared to the non-pregnant state. Also, exposure was lower for women in the second trimester of pregnancy than for non-pregnant women. These findings indicate increased elimination of phenoxymethylpenicillin during mid and late pregnancy, although differences in elimination were non-significant. The authors recommend reduced dosing-interval or increased dose of phenoxymethylpenicillin in pregnant women [1].

Effects

No studies with a clinically relevant sex analysis regarding the effect of phenoxymethylpenicillin have been found.

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of phenoxymethylpenicillin have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Updated: 2021-02-12

Date of litterature search: 2021-01-11

References

  1. Heikkilä AM, Erkkola RU. The need for adjustment of dosage regimen of penicillin V during pregnancy. Obstet Gynecol. 1993;81:919-21. PubMed
  2. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.] länk

Authors: Linnéa Karlsson Lind

Reviewed by: Diana Rydberg

Approved by: Karin Schenck-Gustafsson